Seres Therapeutics, Inc. (MCRB) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
85.97
↓-44% vs avg
5yr avg: 152.58
30Y Low17.6·High152.6
P/B Ratio
↓
1.55
↓-92% vs avg
5yr avg: 18.57
30Y Low3.0·High56.1
ROE
↑
19.6%
↓+121% vs avg
5yr avg: -93.5%
30Y Low-352%·High20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MCRB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Seres Therapeutics, Inc. trades at 12.1x earnings, 48% below its 5-year average of 23.3x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 46%. On a free-cash-flow basis, the stock trades at 86.0x P/FCF, 44% below the 5-year average of 152.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $74M | $132M | $129M | $179M | $605M | $764M | $2.0B | $195M | $184M | $410M | $394M |
| Enterprise Value | $112M | $169M | $190M | $250M | $605M | $633M | $1.9B | $175M | $106M | $383M | $351M |
| P/E Ratio → | 12.06 | 23.25 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 94.25 | 167.28 | — | — | — | 5.27 | 58.85 | 5.66 | 6.52 | 12.78 | 18.12 |
| P/B Ratio | 1.55 | 2.98 | 9.37 | — | 56.13 | 5.81 | 11.19 | — | — | 6.76 | 2.97 |
| P/FCF | 85.97 | 152.58 | — | — | — | — | — | — | — | — | 17.59 |
| P/OCF | 66.57 | 118.16 | — | — | — | 114.22 | — | — | — | — | 8.98 |
P/E links to full P/E history page with 30-year chart
MCRB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 214.43 | — | — | — | 4.37 | 56.59 | 5.07 | 3.74 | 11.93 | 16.11 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 195.59 | — | — | — | — | — | — | — | — | 15.63 |
MCRB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Seres Therapeutics, Inc. earns an operating margin of -11910.1%. ROE of 19.6% indicates solid capital efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -423.8% | -423.8% | — | — | — | 100.0% | -172.7% | 100.0% | -239.5% | -178.7% | -276.7% |
| Operating Margin | -11910.1% | -11910.1% | — | — | — | -44.5% | -265.3% | -208.3% | -354.8% | -284.7% | -426.5% |
| Net Profit Margin | 721.9% | 721.9% | — | — | — | -45.2% | -268.3% | -203.7% | -350.0% | -278.4% | -420.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.6% | 19.6% | 1.0% | — | -351.6% | -42.8% | -141.0% | — | -1563.8% | -92.5% | -54.2% |
| ROA | 4.1% | 4.1% | 0.1% | -32.2% | -71.1% | -18.8% | -37.5% | -55.6% | -63.8% | -38.7% | -37.4% |
| ROIC | -90.3% | -90.3% | -180.9% | -806.1% | -2440.3% | -96.6% | -429.2% | — | — | -112.0% | -63.2% |
| ROCE | -86.4% | -86.4% | -67.7% | -74.6% | -67.2% | -22.7% | -46.0% | -87.2% | -84.9% | -45.7% | -41.4% |
MCRB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $37M ($83M total debt minus $46M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.88 | 1.88 | 6.65 | — | 15.08 | 0.37 | 0.23 | — | — | 0.15 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.84 | 4.41 | — | -0.04 | -0.99 | -0.43 | — | — | -0.45 | -0.33 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 43.01 | — | — | — | — | — | — | — | — | -1.95 |
| Interest Coverage | — | — | — | -14.24 | -29.50 | -21.54 | -29.48 | -139.00 | -84.42 | -56.21 | -95.81 |
MCRB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Seres Therapeutics, Inc.'s current ratio of 2.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.78x to 2.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.56 | 2.56 | 0.94 | 1.78 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 |
| Quick Ratio | 2.56 | 2.56 | 0.94 | 1.48 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 |
| Cash Ratio | 2.37 | 2.37 | 0.75 | 1.30 | 2.12 | 3.53 | 5.46 | 2.06 | 2.04 | 4.74 | 6.34 |
| Asset Turnover | — | 0.01 | — | — | — | 0.41 | 0.10 | 0.26 | 0.23 | 0.17 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 166.54 | — | — | — | — | 103.15 | 18.88 | — | — | — |
MCRB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Seres Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 8.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.3% | 4.3% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.2% | 0.7% | — | — | — | — | — | — | — | — | 5.7% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $9M | $8M | $6M | $5M | $5M | $4M | $3M | $2M | $2M | $2M |
Peer Comparison
Compare MCRB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MCRBYou | $74M | 12.1 | — | 86.0 | -423.8% | -11910.1% | 19.6% | -90.3% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MIRM | $5B | -219.0 | 2461.9 | 94.2 | 80.7% | -4.2% | -8.6% | -5.0% | 151.5 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 EVGN | $7M | -0.3 | — | — | 39.8% | -255.4% | -75.8% | -102.4% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 NBIX | $15B | 32.0 | 22.7 | 20.1 | 98.2% | 21.6% | 16.4% | 16.1% | 0.6 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 JNJ | $536B | 38.4 | 18.6 | 27.0 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MCRB vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonMCRB — Frequently Asked Questions
Quick answers to the most common questions about buying MCRB stock.
What is Seres Therapeutics, Inc.'s P/E ratio?
Seres Therapeutics, Inc.'s current P/E ratio is 12.1x. The historical average is 23.3x.
What is Seres Therapeutics, Inc.'s ROE?
Seres Therapeutics, Inc.'s return on equity (ROE) is 19.6%. The historical average is -94.6%.
Is MCRB stock overvalued?
Based on historical data, Seres Therapeutics, Inc. is trading at a P/E of 12.1x. Compare with industry peers and growth rates for a complete picture.
What are Seres Therapeutics, Inc.'s profit margins?
Seres Therapeutics, Inc. has -423.8% gross margin and -11910.1% operating margin.